Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02109172 · ClinicalTrials.gov registry record · Phase 2
A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study of Chronic Obstructive Pulmonary Disease and COPD, sponsored by Mylan.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT02109172 is a Phase 2 study of Chronic Obstructive Pulmonary Disease and COPD that has completed, run by Mylan. The registered enrollment target is 64 participants, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02109172, a Phase 2 study of Chronic Obstructive Pulmonary Disease and COPD, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluated the safety and efficacy of once and twice daily TD-4208 and placebo when administered using a jet nebulizer for 7 days in a cross-over design to patients with moderate to severe chronic obstructive pulmonary disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-4208
Study Locations (1)
North Carolina
- American Health Research - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02109172
The ClinicalTrials.gov registry entry for NCT02109172 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,753-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (96% lower). The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02109172 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02109172 about?
NCT02109172 is a clinical study titled "A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)". This study evaluated the safety and efficacy of once and twice daily TD-4208 and placebo when administered using a jet nebulizer for 7 days in a cross-over design to patients with moderate to severe chronic obstructive pulmonary disease.
What is the current status of trial NCT02109172?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-04. Estimated completion is 2014-10.
What conditions does trial NCT02109172 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, COPD.
What interventions are being tested in trial NCT02109172?
The interventions under investigation include: Placebo (DRUG), TD-4208 (DRUG).
Who is sponsoring clinical trial NCT02109172?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02109172 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.